Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
MALVERN, Pa., March 04, 2016 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the 23rd Annual Future Leaders in the Biotech Industry Conference on Friday, March 11, at 10 a.m. EST at the Millennium Broadway Hotel & Conference Center in New York City.
For additional information on the conference, please visit: http://www.biocentury.com/conferences/futureleaders/dates.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel drugs to treat metabolic and specialty cardiopulmonary disorders. The Company's proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects. PhaseBio's lead development candidates include: PE0139, a novel, super-long-acting basal insulin-ELP fusion for once-weekly dosing; and PB1046, a weekly vasoactive intestinal peptide receptor agonist for the treatment of acute and chronic heart failure, the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, Becker muscular dystrophy and X-linked dilated cardiomyopathy, and other indications. PhaseBio is privately owned with headquarters and research laboratories in Malvern, PA.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
